Showing 4761-4770 of 10638 results for "".
Vaccinating for Adult Shingles: New Initiatives
https://reachmd.com/programs/clinicians-roundtable/vaccinating-for-adult-shingles-new-initiatives/2727/A vaccine for adult Shingles was approved in 2006 by the FDA and is in use today. Yet delivery of this vaccination has not been as widespread as it could and should be. With this in mind, many hospitals and clinics are working to improve on their current approach to its distribution; at some healthColon Cancer Screening Modalities
https://reachmd.com/programs/clinicians-roundtable/colon-cancer-screening-modalities/2555/A colon cancer screening is virtually implicit with colonoscopies. But, when should follow-up exams be performed in patients with varying degrees of risk? Dr. Carol Burke, Director of the Center for Colon Polyp & Cancer Prevention at the Cleveland Clinic, discusses colon cancer screening modalManaging Risk of Medical Errors and Trial Lawyers
https://reachmd.com/programs/clinicians-roundtable/managing-risk-of-medical-errors-and-trial-lawyers/2418/From employers and insurers to the federal Medicare program, the focus on medical errors by those paying for health care is unprecedented. But Dr. Richard Anderson, chairman and chief executive of Napa, Calif-based national malpractice carrier, The Doctors Company, tells the Chicago Tribune's BrucePre-implantation Genetic Diagnosis
https://reachmd.com/programs/advances-in-womens-health/pre-implantation-genetic-diagnosis/2293/Prenatal diagnosis of genetic disorders has traditionally involved testing of an established pregnancy by utilizing chorionic villus sampling or amniocentesis. In the event that an abnormality is detected, pregnancy termination is then offered as an option. Pre-implantation Genetic Diagnosis (PGD)In and Around HDL
https://reachmd.com/programs/lipid-luminations/in-and-around-hdl/2173/Dr. Larry Kaskel welcomes Dr. Daniel Rader to Lipid Luminations. Dr. Rader is Professor of Medicine, Pharmacology, and Pathology and Laboratory Medicine at University of Pennsylvania. He is the Director of Preventive Cardiovascular Medicine and Lipid Clinic Director at General Clinical Research CentEthical Issues Arising in Natural Disasters
https://reachmd.com/programs/focus-on-disaster-medicine-and-preparedness/ethical-issues-arising-in-natural-disasters/1533/Dr. Maurie Pickard speaks with Dr. Michael Brannigan, Vice President of Clinical and Organizational Ethics at the Center for Practical Bioethics in Kansas City, about some of the ethical issues facing medical practitioners during natural disasters. These issues are approached from the macro (federalSmoking Cessation Medication and Treatments
https://reachmd.com/programs/clinicians-roundtable/smoking-cessation-medication-and-treatments/1100/Dr. Larry Kaskel is discusses each of the various smoking cessation options available with Carol Southard, RN, MSN, and an American Lung Association certified instructor with over 20 years experience and proven success. Carol serves as the Tobacco Cessation Consultant for Chicago area hospitals. YouGlobal Warming's Clinical and Political Solutions
https://reachmd.com/programs/clinicians-roundtable/global-warmings-clinical-and-political-solutions/491/In this segment, Dr. Patz discusses the clinical opportunities physicians can employ with their patients to maximize health through awareness of the environmental changes occurring. The talk then flows into the subject of government environmental policies, including states taking the initiative on eTransplant & Treatment Options for Patients with Hepatocellular Carcinoma
https://reachmd.com/programs/advances-in-transplantation/transplant-and-treatment-options-for-patients-with-hepatocellular-carcinoma/6402/While the incidence of many types of cancer in the United States has decreased in recent years, the incidence of hepatocellular carcinoma, secondary to either hepatitis B or cirrhosis, has been on the rise. And, of the treatment options including resection, ablation and transplantation, what tumor cPatient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
https://reachmd.com/clinical-practice/oncology-hematology/patient-reported-outcomes-from-the-phase-3-keynote-689-trial-of-adding-perioperative-pembrolizumab-to-standard-of-care-in-resectable-locally-advanced-hnscc/39777/In KEYNOTE-689, patient-reported outcomes including HRQOL remained stable vs baseline with perioperative pembrolizumab in resectable locally advanced HNSCC.